Plasma products do not solve the inhibitor problem-Reference-Cited by-同舟云学术

Plasma products do not solve the inhibitor problem

Published:2016-12-19 Issue:3 Volume:23 Page:346-347
ISSN:1351-8216
Container-title:Haemophilia
language:en
Short-container-title:Haemophilia

Author:

van den Berg H. M.¹,Pipe S.²,Ljung R.³

Affiliation:

1. Julius Centre for Health Sciences and Primary Care; University Hospital Utrecht; Utrecht The Netherlands

2. Pediatrics; Univ. of Michigan; Ann Arbor MI USA

3. Pediatrics; University of Lund; Malmö Sweden

Publisher

Wiley

Subject

Genetics (clinical),Hematology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/hae.13132/fullpdf

Reference7 articles.

1. Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study;Gouw;Blood,2007

2. Factor VIII products and inhibitor development in severe hemophilia A;Gouw;N Engl J Med,2013

3. Inhibitor development in haemophilia according to concentrate. Four-year results from the European HAemophilia Safety Surveillance (EUHASS) project;Fischer;Thromb Haemost,2015

4. Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma-derived or recombinant factor VIII concentrates: a systematic review;Iorio;J Thromb Haemost,2010

5. Risk for inhibitor development in severe hemophilia A PUPs is not associated with class of FVIII concentrates nor by high von-Willebrand factor or by type of viral inactivation procedure;Hashemi;J Thromb Haemost,2015

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Incidence of inhibitor development in PUPs with severe Haemophilia A in the CEE region between 2005 and 2015;Thrombosis Research;2021-02

2. Lower inhibitor risk of plasma-derived factor VIII concentrates versus recombinant factor VIII concentrates in patients with severe haemophilia A : result from SIPPET study and comments;HEMATOLOGIE;2019

3. Safety of recombinant coagulation factors in treating hemophilia;Expert Opinion on Drug Safety;2019-02-01

4. How I approach: Previously untreated patients with severe congenital hemophilia A;Pediatric Blood & Cancer;2018-09-24

5. Evolving Complexity in Hemophilia Management;Pediatric Clinics of North America;2018-06